Zacks Small Cap Research – LGND: Initiating Coverage – A Prince Among Royalty – Go Health Pro
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreciation and amortization (EBITDA) and earnings estimates. Ligand is a biopharmaceutical royalty … Read more
